RxDoctor Payments Data

Deep Mahapatra

Family Medicine · Perry Hall, MDNPI 1053874115

Payments from drug & device makers

$1,478in general payments, 2019–2025

Across 39 payments — averaging $37.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$458
  • AbbVie$247
  • Lilly USA, LLC$215
  • Silk Road Medical, Inc.$178
  • Pfizer$152
  • Exact Sciences$88
  • plus $139 from 6 others

What the payments were for

  • Food & beverage$1,478100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,478 in reported general payments places this provider in the 70th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$63,078
Medicare patients
256
Services billed
1,294

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide18$29,041
EliquisApixaban20$21,722
MounjaroTirzepatide15$16,553
JardianceEmpagliflozin11$11,358
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$5,943
BystolicNebivolol Hcl11$3,784
Atorvastatin Calcium176$2,568
ValacyclovirValacyclovir Hcl21$2,258
Levothyroxine Sodium150$2,183
Rosuvastatin Calcium121$1,851
Ventolin HfaAlbuterol Sulfate13$1,552
Metoprolol Succinate69$1,536
Pravastatin Sodium51$1,258
SynthroidLevothyroxine Sodium21$1,221
Amlodipine Besylate115$1,180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$22$29,04118 claims
PfizerEliquis$152$21,72220 claims
Lilly USA, LLCMounjaro$215$16,55315 claims
GSKAnoro Ellipta$26$5,94313 claims
AbbVieSynthroid$247$1,22121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Perry Hall

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →